Zacks Investment Research has recently initiated coverage of Utah Medical Products, Inc. UTMD with a Neutral recommendation. This report highlights the company's strong positioning in the growing ...
SALT LAKE CITY, UT / ACCESS Newswire / October 23, 2025 / Utah Medical Products, Inc. (UTMD) reports third quarter (3Q) and first nine months (9M) of calendar year 2025 financial results that were ...
SALT LAKE CITY, Jan. 30, 2020 (GLOBE NEWSWIRE) -- In the final calendar quarter (4Q) of 2019, Utah Medical Products, Inc. (Nasdaq: UTMD) began to realize accretive profits net of the quarterly ...
The 2Q percentage decline in consolidated revenues was less than for 1H primarily because the period-to-period decline in UTMD sales to its previously major biopharmaceutical OEM customer PendoTECH ...
1 Day UTMD 0.24% DJIA -0.20% Russell 2K -0.50% Health Care/Life Sciences -0.42% ...
SALT LAKE CITY, UT / ACCESS Newswire / July 24, 2025 / Utah Medical Products, Inc. [Nasdaq:UTMD] reports second calendar quarter (2Q) and first half (1H) 2025 financial results which are consistent ...
1 Day UTMD 0.56% DJIA 0.25% Russell 2K 0.56% Health Care/Life Sciences -0.37% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results